The Week

Abbott Laboratories posted a strong week, gaining 4.84% to close at $116.64. The stock decisively outperformed the S&P 500, which fell 1.43%, by roughly 6.27 percentage points. The week started with a dip to the intraweek low of $109.35 on Monday, before mounting a steady rally. The uptrend firmed through midweek, and Friday saw a breakout on the highest daily volume of the week, with the stock hitting $116.66 intraday before settling at $116.64. Weekly amplitude reached 6.64%. Average daily volume stood at around 8.87 million shares, about 18% below the 60-day median, though Friday’s 9.93 million shares signalled renewed conviction.

Key Events

The week’s dominant narrative was Abbott’s move to resolve its long-running preterm infant formula litigation. The company agreed to a settlement totalling approximately $670 million, sidestepping the appeals process related to a prior $495 million verdict. The agreement removes a significant legal overhang, and the stock responded positively to the clarity.

On the business front, Abbott and the NACHC launched a nationwide ‘Food for Health’ initiative, embedding nutritious food into the healthcare framework. Separately, the HealthTab platform by Avricore Health entered a multi-year collaboration with Abbott to distribute point-of-care testing across the UK. In diabetes care, MiniMed began shipping its smallest app-controlled insulin pump alongside the world’s smallest sensor, reinforcing the company’s competitive edge in the space.

Abbott also declared a third-quarter 2026 dividend of R$0.18 per unit, continuing its commitment to shareholder returns.

Analyst Ratings

A total of 28 analysts cover the stock: 17 rate it buy, 4 rate it overweight, 6 rate it hold, and 1 has no opinion. No analysts rate it underweight or sell. The consensus recommendation is ‘buy’, with a consensus target of $120.20, implying roughly 3.1% upside from the current price. Target prices range from $103 to $135, reflecting a fairly wide spread that suggests differing views on how quickly the litigation de-risking will be priced in. Abbott ranks 7th out of 140 companies in the medical devices industry, placing it near the top of the peer group.

The Week Ahead

Investors will watch for further details on the settlement, particularly the specific terms and any financial implications. On the macro side, the US releases housing data including FHFA and Case-Shiller home price indices, consumer confidence, and new home sales. The tone of this data could influence broader risk appetite and spill over into the healthcare sector.

In Short

Abbott delivered a week of outperformance driven almost entirely by the removal of a major litigation risk. The analyst community is broadly constructive, yet the consensus target sits just above spot and the wide target range signals that much of the relief rally may already be priced in. The latest session’s fund flow showed large-lot money turning net seller, while retail and medium-sized orders were net buyers. The stock now enters a watchful phase where further upside likely hinges on fresh business catalysts and the settlement details expected in the coming weeks.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.